Objective. To assess the prevalence of mumps antibodies in children and adolescents of Mexico, two years after the introduction of the mumps-containing vaccine MMR. Materials and methods. Evaluation of IgG antibodies with a commercial kit of indirect ELISA. Results. 2 111 children (1-9 years) and 2 484 adolescents (10-19 years) were studied. The overall antibody seroprevalence was 70.6% (95% CI 69.3- 71.9), being higher in adolescents (83.0%, 95%CI 81.5-84.5) than in children (56.0%, 95%CI: 53.9-58.11) (OR 3.83, 95%CI 3.34-4.39, p=0.0000000). Children 1 to 2 and 6 to 9 years who were part of the target group of mumps vaccination since 1998, they had higher seroprevalence than the group of 3 to 5 years unvaccinated. Conclusions. Seropositivity in children aged 1 to 2 and 6 to 9 years was probably attributable to vaccination during 1998-2000 and in other age groups to natural exposure related to time elapsed in each birth cohort until the study recruitment.
CITATION STYLE
Méndez-Herrera, A., Arias-Toledo, E., Sánchez-Alemán, M., Olamendi-Portugal, M. L., Ruiz-Gómez, J., & Díaz-Ortega, J. L. (2018). Prevalencia de anticuerpos frente a parotiditis en niños y adolescentes a dos años de haberse introducido la vacuna SRP. Salud Publica de Mexico, 60(1), 71–76. https://doi.org/10.21149/8138
Mendeley helps you to discover research relevant for your work.